Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Curosurf (Poractant Alfa) Market In 2029?
In recent years, the market size for curosurf (poractant alfa) has registered an XX% growth (HCAGR). It’s estimated to expand from $XX million in 2024 to $XX million by 2025, reflecting a compound annual growth rate (CAGR) of XX%. The historical period’s expansion is credited to the heightened demand for sophisticated medical solutions, synthetic surfactants in cleanliness products, enhanced consciousness about healthcare and improved healthcare accessibility, a rising preference for uncomplicated cleaning methods promoting synthetic surfactant sales, and an overall increase in healthcare awareness.
What Growth Rate Is Forecasted for the Curosurf (Poractant Alfa) Market by 2029?
The market of curosurf (poractant alfa) is predicted to experience a growth rate of XX (FCAGR) in the coming years, reaching $XX million by 2029 with a compounded annual growth rate (CAGR) of XX%. This growth during the forecasted period can be associated with the increased levels of premature births, an increase in the application of synthetic surfactants in agrochemicals, a sharp rise in chronic respiratory disease cases, more spending on healthcare, and a growing inclination towards respiratory infection treatment. Key trends anticipated during this period are the adoption of microdosing methodologies, incorporation of surfactant therapy, embracement of biologic and immunomodulatory therapies, movement towards environmentally friendly and sustainable surfactants, and attention to neonatal and pediatric care.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp
Which Key Companies Are Shaping the Future of the Curosurf (Poractant Alfa) Market?
Major companies operating in the curosurf (poractant alfa) market include Chiesi Farmaceutici S.p.A
Which Factors Are Driving Demand in the Curosurf (Poractant Alfa) Industry?
The surge in respiratory disorders is anticipated to fuel the advancement of the curosurf (poractant alfa) market in the future. The term “respiratory disorders” encompasses common conditions that impact the lungs and affect breathing; these include ailments such as asthma, COPD, and lung cancer, which tend to lead to hindered breathing and diminished lung functionality. The escalating instances of respiratory disorders can be attributed to increasing air pollution, which often worsens conditions like asthma, and an aging population, which tends to have a higher occurrence of age-specific diseases, including COPD. Poractant alfa is utilized as a treatment option for neonatal respiratory distress syndrome; it enhances lung function and simplifies the breathing process in premature babies via administration through an endotracheal tube. For example, in Australia, according to the National Asthma Council—an Australian not-for-profit organization—in November 2023, the country numbered 467 asthma-related fatalities in 2022, with 299 females and 168 males accounted for; these figures indicate a rise from the 355 deaths documented in 2021. As such, the escalating instances of respiratory disorders are propelling the growth of the curosurf (poractant alfa) market. The increase in premature births is predicted to give rise to the expansion of the Curosurf (poractant alfa) market in the coming years. Premature births refer to babies born prior to 37 weeks of gestation; for perspective, a regular term pregnancy is usually about 40 weeks. The noted increase in premature births can be associated with older maternal age and the augmented use of assisted reproductive technologies, which often result in multiple pregnancies. Poractant alfa is leveraged as a treatment for infants born prematurely with respiratory distress syndrome—it minimizes lung surface tension, helps in keeping the lungs open, and boosts oxygen exchange capabilities. For example, according to the Office for National Statistics—a government department based in the UK—in May 2024, England and Wales saw a premature live birth rate of 7.9% in 2022, a rise from the 7.5% noted in 2021. Therefore, the growing prevalence of premature births is causing a surge in the growth of the Curosurf (poractant alfa) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19893&type=smp
How Is the Curosurf (Poractant Alfa) Market Segmented by Several Divisions?
The curosurf (poractant alfa)market covered in this report is segmented –
1) By Type: Natural Poractant Alfa; Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales; Distribution Channels; Online Marketplace
3) By Application: Pulmonary Edema; Respiratory Distress Syndrome; Other Respiratory Disorders
4) By End User: Hospitals; Clinics; Ambulance Services
What are the Emerging Market Trends Driving the Growth of the Curosurf (Poractant Alfa) Industry?
A significant development in the curosurf (poractant alfa) market is the concentration on creating innovative treatments, particularly a new inhaled gene therapy to cater to unaddressed needs in respiratory ailments. This advanced therapy involves the direct delivery of therapeutic genes to the lungs through inhalation, typically via aerosolized particles or nanoparticles. As an example, AlveoGene, a gene therapy developer based in the UK, was granted the Rare Pediatric Disease Designation (RPDD) by the FDA in November 2024 for AVG-002. This new inhaled gene therapy targets the lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic disorder causing respiratory failure in newborns. Treatment options for SP-B deficiency, which arises from mutations in the SFTPB gene, are currently limited and mostly involve lung transplantation. AVG-002 employs AlveoGene’s InGenuity platform for direct delivery of a functional SP-B gene to the lungs which has demonstrated promising results in early laboratory studies.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-
Which Regions Are Driving Growth in the Curosurf (Poractant Alfa) Market?
North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19893
This Report Delivers Insight On:
1. How big is the curosurf (poractant alfa) market, and how is it changing globally?
2. Who are the major companies in the curosurf (poractant alfa) market, and how are they performing?
3. What are the key opportunities and risks in the curosurf (poractant alfa) market right now?
4. Which products or customer segments are growing the most in the curosurf (poractant alfa) market?
5. What factors are helping or slowing down the growth of the curosurf (poractant alfa) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model